ClinicalTrials.gg
RecruitingNCT06906601MAGNETOUpdated Oct 20, 2026

Preoperative Magnetic Tracking in Breast Surgery in France: French Medical-economic Study.

An observational study in Breast Cancer, Medico-economic Impact and Breast Cancer Surgery, sponsored by Centre Leon Berard. Recruiting at 7 sites in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Centre Leon Berard · Observational

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
772
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Breast Neoplasms by Centre Leon Berard — 5 open to participants now, 8 under way, none of them phase 3. Breast Neoplasms · Centre Leon Berard.

Started
2025
the only one that year
Observational
7 of 23
4 open now
Registered
22nd of 23
by date

Among the 23 studies in Breast Neoplasms by Centre Leon Berard, this one is the only one that started in 2025, is one of 7 observational ones, and was the 22nd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

5 of the 23 studies in Breast Neoplasms by Centre Leon Berard are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Breast Neoplasms by Centre Leon Berard, or all of them as a file.
02

Study summary

MAGNETO is a French medico-economic study on preoperative localization in breast cancer surgery. The main objective is to conduct a cost-consequence analysis comparing magnetic clip localization with the use of metallic wires for the preoperative identification of non-palpable breast lesions. The choice of localization method is left to the physician's and center's discretion. The study is non-interventional (with only questionnaires and data collection), prospective, and multicenter, with patient follow-up lasting up to six months after breast surgery.

Read the detailed description

The MAGNETO study is a non-interventional, prospective, and multicenter study. It includes two cohorts: one using magnetic clip localization and the other using metallic wire localization.

Patients are enrolled by the surgeon during the preoperative consultation validating the conservative surgery with preoperative localization. The choice of cohort is left to the discretion of the center based on their routine practice. Baseline data, including patient and disease characteristics, are collected.

Depending on the assigned cohort, localization is performed either with a magnetic clip or a metallic wire. A mammogram is then performed to assess the correct positioning of the marker and its distance from the target lesion. At this stage, the radiologist completes a Likert scale satisfaction questionnaire.

Breast-conserving surgery is performed according to the hospital's standard practices. On the day of the procedure, the surgeon also completes a Likert scale satisfaction questionnaire.

Patients complete quality of life (EQ-5D-5L) and satisfaction questionnaires at several points throughout the study. Postoperative complications are also recorded.

03

Conditions studied

  • Breast Cancer
  • Medico-economic Impact
  • Breast Cancer Surgery

Keywords

  • cancer
  • breast cancer
  • breast cancer surgery
  • preoperative localization
  • magnetic clip
  • wire localization
  • health economic study
  • Cost-consequence analysis
  • medico-economic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients recruited in 7 centers spread across France

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • I1. Female aged ≥ 18 years;
  • I2. Patient presenting with a unifocal and unilateral lesion of invasive carcinoma or in situ;
  • I3. Indication for first breast-conserving treatment with the need for preoperative localization of the lesion, regardless of the associated lymph node procedure;
  • I4. Patient affiliated with a health insurance system;
  • I5. Non-opposition to the study.

Exclusion criteria

Exclusion Criteria:

  • E.1. Psychological, family, or sociological condition that may potentially compromise adherence to the treatment protocol and follow-up;
  • E.2. Bilateral surgery required;
  • E.3. Patient with breast cancer;
  • E.4. Multifocal or benign lesions;
  • E.5. Pregnant or breastfeeding patient;
  • E.6. Need for treatment;
  • E.8. Patient under guardianship, curatorship, or deprived of liberty.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
772 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes

Groups and cohorts

  • magnetic clip localization

    The preoperative localization can be performed using several techniques, magnetic clip localization will be use in this cohort

    Procedure: magnetic clip localization · Procedure: Breast cancer surgery

  • wire localization

    The preoperative localization can be performed using several techniques, wire localization will be use in this cohort

    Procedure: metallic wire localization. · Procedure: Breast cancer surgery

Interventions

  • Proceduremagnetic clip localization

    magnetic clip localization for preoperative localization for breast cancer surgery

  • Proceduremetallic wire localization.

    metallic wire localization for preoperative localization for breast cancer surgery

  • ProcedureBreast cancer surgery

    Patient with invasive or in situ breast carcinoma, presenting with a unifocal and unilateral lesion, requiring a first-line breast-conserving treatment with preoperative localization, regardless of the associated lymph node procedure

06

What researchers measure

Primary outcomes

  1. Comparison of the average total cost of patient care with magnetic clip localization versus the use of a hookwire, up to 6 months post-surgery

    Effectiveness of localization in terms of lesion identification (did the localization, based on the pathological report, allow the lesion to be located in the breast?) * Rate of clear margins (for isolated in situ lesions: margin ≥ 2 mm, and for invasive cancers: non-zero margin) * Percentage of patients requiring re-intervention due to an unclear margin * Measured distance between the marker and the target lesion during the procedure * Ratio between the weight of the resected specimen and the lesion size in g/mm² * Patient satisfaction with their care, assessed using a 5-point Likert scale during the postoperative consultation (between day 15 and day 30 after resection) * Radiologist satisfaction with the marker placement, assessed using a 5-point Likert scale immediately after placement * Surgeon satisfaction with lesion localization, assessed using a 5-point Likert scale at the end of the surgery.

    Time frame: 6 months post surgery

Secondary outcomes

  1. Quality of life of patientes

    Quality of life assessed using the 5-level EQ-5D version (EQ-5D-5L).The questionnaire assesses 5 dimensions (Mobility, Self-care, Usual activities, Pain/Discomfort, Anxiety/Depression). Each dimension is rated on 5 levels (from 1 = no problems to 5 = extreme problems).

    Time frame: At inclusion, 15 to 30 days after surgery and 6 months after surgery

  2. Satisfaction of radiologist and surgeon

    Questionnaire to evaluate the satisfaction of radiologist after the maker placement and questionnaire to evaluate the satisfaction of surgeon after the surgery. The score isn't on a scale.

    Time frame: Within 24 hours after the maker placement and within 24 hours after the surgery

  3. Patient satisfaction and experience.

    Questionnaire after the surgery to evaluated the patient satisfaction and experience. The score isn't on a scale.

    Time frame: 15 to 30 days after surgery

  4. Budget impact analysis of pre operative magnetic clip localization versus the use of a hookwire.

    The decision to include a Budget Impact Analysis (BIA) in this study is in line with the framework agreement signed in January 2016 between the Economic Committee for Medicinal Products (Comité Economique des Produits de Santé - CEPS, in French) and the Pharmaceutical Industry (Les Entreprises du Médicament - LEEM, in French), which advises the implementation of a BIA in addition to the medico-economic study. The BIA will strictly comply with the HAS requirements presented in its methodological guide for BIA. A budget impact model (BIM) will be developed with the French National health insurance perspective. The cost of the current (hookwire) or new intervention (magnetic clip) mix will be assessed. The population to be included in a BIA will be all patients eligible in France for the new intervention during the time horizon of 3 years. The results will be expressed in incremental budget impact in the first, second and third year.

    Time frame: At 1, 2 and 3 years

  5. The organisationnal impact of magnetic clip versus metallic wires.

    The organizational analysis will be based on performance indicators of magnetic clips compared to metallic wires, such as the number of patient visits to the hospital before surgery, the number of localization procedures performed on the day of the intervention, the length of stay, waiting times, and the number of emergency visits throughout the follow-up period. The stochastic variables (lengths of stay, intervals between stays) will be modeled using appropriate statistical distributions, determined by maximum likelihood estimation based on statistical analyses of the extracted data.

    Time frame: At 6 months

07

Study locations

6 of 7 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Oct 2027, 30 months after the start.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 30 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2025
First posted
Apr 2, 2025
StartActual
Apr 15, 2025
Primary completionEst.
Oct 15, 2027
CompletionEst.
Oct 15, 2027
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Centre Léon Bérard · Lyon, FranceContact added S•••@lyon.unicancer.fr · •••2828
  • Hôpital Nord -Ouest Val d'Oise (NOVO) · Pontoise, FranceContact s•••@ght-novo.fr · •••4040→f•••@ght-novo.fr · •••4040
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Centre Léon Bérard · Lyon, FranceContact added S•••@lyon.unicancer.fr · •••2828
    • Hôpital Nord -Ouest Val d'Oise (NOVO) · Pontoise, FranceContact s•••@ght-novo.fr · •••4040→f•••@ght-novo.fr · •••4040
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06906601
Lead sponsor
Centre Leon Berard
Responsible party
Sponsor
First posted
Apr 2, 2025
Start date
Apr 15, 2025
Primary completion
Oct 15, 2027 (estimated)
Completion
Oct 15, 2027 (estimated)
Last update
Oct 20, 2026

Study contacts

Severine Metzger
Contact
severine.metzger@lyon.unicancer.fr
+33 (0)4 78 78 27 86
Marie Osdoit, Dr
Contact
Marie.OSDOIT@lyon.unicancer.fr

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion